Last reviewed · How we verify
Alphacalcidol — Competitive Intelligence Brief
phase 2
Sodium-dependent noradrenaline transporter, Vitamin D3 receptor
Nephrology
Small molecule
Live · refreshed every 30 min
Target snapshot
Alphacalcidol (Alphacalcidol) — University of Ioannina.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Alphacalcidol TARGET | Alphacalcidol | University of Ioannina | phase 2 | Sodium-dependent noradrenaline transporter, Vitamin D3 receptor |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Alphacalcidol CI watch — RSS
- Alphacalcidol CI watch — Atom
- Alphacalcidol CI watch — JSON
- Alphacalcidol alone — RSS
Cite this brief
Drug Landscape (2026). Alphacalcidol — Competitive Intelligence Brief. https://druglandscape.com/ci/alphacalcidol. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing